Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of furocoumarin compounds in preparation of anti-hepatitis B virus (HBV) medicaments

A technology of hepatitis B virus and furanocoumarin, which is applied in the direction of antiviral agents, active ingredients of heterocyclic compounds, etc., can solve the problems of lack of drug resistance and achieve the effect of simple structure, low toxicity and easy synthesis

Inactive Publication Date: 2013-07-10
广州市爱菩新医药科技有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved by the present invention is to overcome the deficiency in the prior art of lack of drugs that are not easily resistant to drugs and can cure hepatitis B virus, and provide a class of furanocoumarin compounds in the preparation of anti-hepatitis B virus (HBV) drugs Applications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of furocoumarin compounds in preparation of anti-hepatitis B virus (HBV) medicaments
  • Application of furocoumarin compounds in preparation of anti-hepatitis B virus (HBV) medicaments
  • Application of furocoumarin compounds in preparation of anti-hepatitis B virus (HBV) medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Embodiment 1: computer drug screening

[0046] Compound library preprocessing: The compound library is a self-prepared compound database. The compound library is processed as follows: removing ions and complexing water molecules, adding charges, protonating, and generating three-dimensional conformations. These processes were completed in the drug design software package Discovery Studio 2.5. The protonation is carried out at pH 6.5~8.5. Prepare small molecule libraries for virtual screening.

[0047] A substructure search was performed with the furanocoumarin structure to find compounds containing the parent nucleus. The present invention predicts that there are 13 candidate inhibitors of human NF-κB target in the compound reserve library of the laboratory through the computer drug screening program DiscoveryStudio version 2.5. The 13 compounds were screened for their anti-HBV replication activity at the cellular level, and 8 of them (N1-N8) were found to inhibit H...

Embodiment 2

[0052] Example 2: Determination of the Toxicity of Compounds to Host Cells

[0053] S1. Cell culture.

[0054] HepG2.2.15 cells (human liver cancer cells transfected with HBV gene, which can stably express HBV virus particles and HBV-related proteins) were cultured in vitro. Use RPMI 1640 medium containing 10% fetal bovine serum and 200mg / L G418 at 37°C and 5% carbon dioxide concentration for routine maintenance and passage.

[0055] S2. Compound intervention.

[0056] Collect logarithmic phase cells and make the cell suspension concentration 5×10 4 cells / ml, added to 96-well cell culture plate. After culturing in a carbon dioxide incubator for 24 hours, the culture solution was replaced with a medium containing different compound concentrations, and the culture was continued for 6 days, and the medium with the same compound concentration was replaced every 3 days. The cytotoxicity was detected on the 6th day, and DMSO was used to The compounds to be tested are formulated ...

Embodiment 3

[0064] Example 3 N1 ~ N8 compounds in Table 1 inhibit the expression of HBsAg and HBeAg antigens

[0065] S1. Cell culture.

[0066] HepG2.2.15 cells were cultured in vitro. Use RPMI 1640 medium containing 10% fetal bovine serum and 200mg / L G418 at 37°C and 5% carbon dioxide concentration for routine maintenance and passage.

[0067] S2. Drug intervention.

[0068] Adjust the logarithmic growth phase HepG2.2.15 cell density to 5×10 4 cells / ml, seeded in a 96-well culture plate, 100 μl per well, after 24 hours, the cells were attached to the bottom of the well, the supernatant was discarded, and the culture solution containing different concentrations of drugs was added, and 3 replicate wells were set for each concentration. Add the cells with complete medium as normal control, 5% CO 2 , Cultivate at 37°C, and change the concentration of the same drug solution once every three days.

[0069] S3. Test method.

[0070] The cell supernatant was collected on the 6th day, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicament application, and in particular discloses application of furocoumarin compounds in preparation of anti-hepatitis B virus (HBV) medicaments. The compounds are different from current commercial anti-HBV medicaments, and belong to non-nucleoside compounds; cytological experimental studies show that the compounds can inhibit the replication of HBV DNA (deoxyribonucleic acid) and the secretion of HBsAg and HBeAg; and cytotoxicity tests show that the compounds have very low toxicity, so the compounds can be safely used for preparing the medicaments for treating and / or preventing related diseases caused by HBV infection.

Description

technical field [0001] The present invention relates to the field of pharmaceutical application inventions, in particular to the application of a class of furanocoumarin compounds in the preparation of anti-hepatitis B virus (HBV) medicaments. Background technique [0002] Hepatitis B Virus (HBV) is a small DNA virus belonging to the family Hepatophagoviridae. The virus was discovered by Dane in 1965 and named Dane particle (Seeger and Mason 2000). HBV specifically infects liver cells, causing inflammation of liver cells, resulting in hepatitis B (Heptatis B). During HBV replication, cccDNA produced is difficult to eradicate and easily leads to chronic hepatitis B (Bowden, Jackson et al. 2004). Epidemiological studies have confirmed that: HBV infection is an important factor in the occurrence of chronic hepatitis, and it is also the main cause of serious liver diseases such as liver cirrhosis and liver cancer (Perz, Armstrong et al. 2006). HBV infection has posed a major ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/37A61P31/20
Inventor 徐峻黄丹娥
Owner 广州市爱菩新医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com